A novel, ataxic mouse model of Ataxia Telangiectasia caused by a clinically relevant nonsense mutation

  1. Harvey Perez
  2. May F Abdallah
  3. Jose I Chavira
  4. Angelina S Norris
  5. Martin T Egeland
  6. Karen L Vo
  7. Callan L Buechsenschuetz
  8. Valentina Sanghez
  9. Jeannie L Kim
  10. Molly Pind
  11. Kotoka Nakamura
  12. Geoffrey G Hicks
  13. Richard A Gatti
  14. Joaquin Madrenas
  15. Michelina Iacovino
  16. Peter McKinnon
  17. Paul J Mathews  Is a corresponding author
  1. The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, United States
  2. University of Manitoba, Canada
  3. University of California, Los Angeles, United States
  4. St Jude Children's Research Hospital, United States

Abstract

Ataxia Telangiectasia (A-T) and Ataxia with Ocular Apraxia Type 1 (AOA1) are devastating neurological disorders caused by null mutations in the genome stability genes, A-T mutated (ATM) and Aprataxin (APTX), respectively. Our mechanistic understanding and therapeutic repertoire for treating these disorders is severely lacking, in large part due to the failure of prior animal models with similar null mutations to recapitulate the characteristic loss of motor coordination (i.e., ataxia) and associated cerebellar defects. By increasing genotoxic stress through the insertion of null mutations in both the Atm (nonsense) and Aptx (knockout) genes in the same animal, we have generated a novel mouse model that for the first time develops a progressively severe ataxic phenotype associated with atrophy of the cerebellar molecular layer. We find biophysical properties of cerebellar Purkinje neurons are significantly perturbed (e.g., reduced membrane capacitance, lower action potential thresholds, etc.), while properties of synaptic inputs remain largely unchanged. These perturbations significantly alter Purkinje neuron neural activity, including a progressive reduction in spontaneous action potential firing frequency that correlates with both cerebellar atrophy and ataxia over the animal’s first year of life. Double mutant mice also exhibit a high predisposition to developing cancer (thymomas) and immune abnormalities (impaired early thymocyte development and T-cell maturation), symptoms characteristic of A-T. Lastly, by inserting a clinically relevant nonsense-type null mutation in Atm, we demonstrate that Small Molecule Read-Through (SMRT) compounds can restore ATM production, indicating their potential as a future A-T therapeutic.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting source data files.

Article and author information

Author details

  1. Harvey Perez

    Neurology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. May F Abdallah

    Neurology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Jose I Chavira

    Neurology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Angelina S Norris

    Neurology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Martin T Egeland

    Neurology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Karen L Vo

    Neurology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Callan L Buechsenschuetz

    Undergraduate Studies, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Valentina Sanghez

    Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Jeannie L Kim

    Neurology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Molly Pind

    Biochemistry and Medical Genetics, University of Manitoba, Manitoba, Canada
    Competing interests
    The authors declare that no competing interests exist.
  11. Kotoka Nakamura

    Laboratory Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Geoffrey G Hicks

    Department of Biochemistry and Medical Genetics, University of Manitoba, Manitoba, Canada
    Competing interests
    The authors declare that no competing interests exist.
  13. Richard A Gatti

    Department of Laboratory Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Joaquin Madrenas

    Medicine, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6191-3733
  15. Michelina Iacovino

    Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Peter McKinnon

    St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Paul J Mathews

    Neurology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, United States
    For correspondence
    pmathews@ucla.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1991-0798

Funding

National Institute of Neurological Disorders and Stroke (R21NS108117)

  • Paul J Mathews

Sparks (13CAL01)

  • Richard A Gatti

National Institute of Neurological Disorders and Stroke (R33NS096044)

  • Michelina Iacovino

National Institute of Neurological Disorders and Stroke (R21NS108117-01S1)

  • Paul J Mathews

National Institute of Neurological Disorders and Stroke (R03NS103066)

  • Paul J Mathews

American Lebanese and Syrian Associated Charities of St. Jude Children's Hospital (N/A)

  • Peter McKinnon

National Institute of Neurological Disorders and Stroke (R01NS037956)

  • Peter McKinnon

National Cancer Institute (P01CA096832)

  • Peter McKinnon

National Center for Advancing Translational Sciences (UL1TR001881)

  • Paul J Mathews

Manitoba Research Innovation (312864)

  • Geoffrey G Hicks

Cancer Care Manitoba Foundation (761023032)

  • Geoffrey G Hicks

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All the animals were handled according to approved institutional animal care and use committee (IACUC) protocols at The Lundquist Institute (31374-03, 31773-02) and UCLA (ARC-2007-082, ARC-2013-068). The protocol was approved by the Committee on the Ethics of Animal Experiments of the Lundquist Institute (Assurance Number: D16-00213). Every effort was made to minimize pain and suffering by providing support when necessary and choosing ethical endpoints.

Copyright

© 2021, Perez et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,661
    views
  • 320
    downloads
  • 13
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Harvey Perez
  2. May F Abdallah
  3. Jose I Chavira
  4. Angelina S Norris
  5. Martin T Egeland
  6. Karen L Vo
  7. Callan L Buechsenschuetz
  8. Valentina Sanghez
  9. Jeannie L Kim
  10. Molly Pind
  11. Kotoka Nakamura
  12. Geoffrey G Hicks
  13. Richard A Gatti
  14. Joaquin Madrenas
  15. Michelina Iacovino
  16. Peter McKinnon
  17. Paul J Mathews
(2021)
A novel, ataxic mouse model of Ataxia Telangiectasia caused by a clinically relevant nonsense mutation
eLife 10:e64695.
https://doi.org/10.7554/eLife.64695

Share this article

https://doi.org/10.7554/eLife.64695

Further reading

    1. Neuroscience
    Mihály Vöröslakos, Yunchang Zhang ... György Buzsáki
    Tools and Resources

    Brain states fluctuate between exploratory and consummatory phases of behavior. These state changes affect both internal computation and the organism’s responses to sensory inputs. Understanding neuronal mechanisms supporting exploratory and consummatory states and their switching requires experimental control of behavioral shifts and collecting sufficient amounts of brain data. To achieve this goal, we developed the ThermoMaze, which exploits the animal’s natural warmth-seeking homeostatic behavior. By decreasing the floor temperature and selectively heating unmarked areas, we observed that mice avoided the aversive state by exploring the maze and finding the warm spot. In its design, the ThermoMaze is analogous to the widely used water maze but without the inconvenience of a wet environment and, therefore, allows the collection of physiological data in many trials. We combined the ThermoMaze with electrophysiology recording, and report that spiking activity of hippocampal CA1 neurons during sharp-wave ripple events encode the position of mice. Thus, place-specific firing is not confined to locomotion and associated theta oscillations but persist during waking immobility and sleep at the same location. The ThermoMaze will allow for detailed studies of brain correlates of immobility, preparatory–consummatory transitions, and open new options for studying behavior-mediated temperature homeostasis.

    1. Neuroscience
    Sergio Casas-Tinto, Nuria Garcia-Guillen, María Losada-Perez
    Short Report

    As the global population ages, the prevalence of neurodegenerative disorders is fast increasing. This neurodegeneration as well as other central nervous system (CNS) injuries cause permanent disabilities. Thus, generation of new neurons is the rosetta stone in contemporary neuroscience. Glial cells support CNS homeostasis through evolutionary conserved mechanisms. Upon damage, glial cells activate an immune and inflammatory response to clear the injury site from debris and proliferate to restore cell number. This glial regenerative response (GRR) is mediated by the neuropil-associated glia (NG) in Drosophila, equivalent to vertebrate astrocytes, oligodendrocytes (OL), and oligodendrocyte progenitor cells (OPCs). Here, we examine the contribution of NG lineages and the GRR in response to injury. The results indicate that NG exchanges identities between ensheathing glia (EG) and astrocyte-like glia (ALG). Additionally, we found that NG cells undergo transdifferentiation to yield neurons. Moreover, this transdifferentiation increases in injury conditions. Thus, these data demonstrate that glial cells are able to generate new neurons through direct transdifferentiation. The present work makes a fundamental contribution to the CNS regeneration field and describes a new physiological mechanism to generate new neurons.